On August 6, 2026, the Senate Homeland Security and Governmental Affairs Committee voted along party lines to hold Dr. Anthony Fauci in contempt of Congress. The vote followed Dr. Fauci’s refusal to answer questions during a July 29, 2026, hearing regarding the federal government’s COVID-19 response. The Committee referred the matter to the Department of Justice, which will decide whether to pursue prosecution. The vote highlights an increasingly aggressive posture toward congressional subpoena enforcement and raises immediate, practical questions for witnesses who may face similar demands.
The Fifth Amendment and Pardon Questions
At the July hearing, Dr. Fauci invoked the Fifth Amendment privilege against self-incrimination more than one hundred times, citing his belief that Committee Chairman Rand Paul (R-Ky.) had an “obsession” with calling for Dr. Fauci’s prosecution. Chairman Paul and other Republican Senators on the Committee asserted that Dr. Fauci’s January 2025 presidential pardon, which covered actions from 2014 through the date of the pardon, left him without a valid basis to invoke the Fifth Amendment, arguing that the pardon removed the risk of federal criminal liability that justifies invoking the privilege. Chairman Paul further argued that Dr. Fauci waived any remaining privilege by delivering an opening statement at the hearing before declining to answer substantive questions from the Senators.
Democratic Senators on the Committee objected to Chairman Paul’s referral to the Department of Justice, with several arguing that the full Senate should consider the resolution and that the Committee should also first hear from legal experts or Dr. Fauci’s counsel on whether the Fifth Amendment privilege was appropriately asserted by Dr. Fauci. For his part, Chairman Paul said that he did not “want to waste time” putting the contempt resolution to a full Senate vote, as the Senate has done in the past.
These questions are far from settled. A Congressional Research Service (“CRS”) Legal Sidebar published two days before the vote outlined a useful framework for understanding the application of the Fifth Amendment privilege in congressional hearings. CRS suggested that the application of the federal statue addressing a witness’s “refus[al] to answer any question pertinent” to a congressional hearing, 2 U.S.C. § 192, hinges on whether the relevant committee “accepts a witness’s assertion of the privilege.” In a case where the committee does not accept the assertion, makes a clear demand for an answer, and the witness again asserts the Fifth Amendment in response, the CRS report suggested that the ensuing court case is the proper venue to consider the privilege. Questions remain about the propriety of a referral without a vote by the full Senate—as CRS has observed, the congressional contempt statute “does not expressly require approval of the contempt citation” by the full chamber, but “both congressional practice and at least one judicial decision [Wilson v. United States] suggest that approval by the committee’s chamber may be necessary.”
The CRS report also noted that, unlike in criminal trials, a witness testifying before a congressional committee may stop testifying on Fifth Amendment grounds at any point, so long as the witness has not yet admitted incriminating facts. On the presidential pardon question, CRS noted that a pardoned witness may still be able to assert the privilege if the witness remains at risk of state prosecution, because the Fifth Amendment right against self-incrimination applies to both federal and state prosecutions.
The legal questions presented by Dr. Fauci’s situation—the interplay of a presidential pardon, partial testimony, and the scope of the privilege before Congress—do not have clear, controlling precedent. Witnesses facing congressional testimony should expect committees to challenge privilege assertions aggressively and treat Department of Justice referrals as a live enforcement threat. The vote also arrived amid renewed attention to congressional contempt enforcement. In late July, the D.C. Circuit affirmed Peter Navarro’s contempt conviction in a separate dispute about assertions of executive privilege in response to congressional demands, underscoring that privilege assertions and subpoena strategy remain high-stakes issues for congressional witnesses.
What This Means for Witnesses
These developments carry several practical lessons for individuals and organizations facing or anticipating congressional inquiries.
- Prepare privilege positions before appearing. Witnesses should develop a clear, defensible privilege strategy, grounded in specific legal authority, well before any hearing or deposition. Ad hoc assertions are vulnerable to waiver arguments and political characterization.
- Avoid categorical non-engagement. Blanket refusals—without particularized objections or attempts to negotiate scope—may heighten contempt risk and could weaken a witness’s legal position if enforcement proceeds.
- Account for parallel legal, political, reputational, and media risks. Congressional investigations operate at the intersection of legal exposure, political messaging, public relations, and regulatory oversight. A strategy that addresses only the legal dimension may leave a witness exposed on other fronts.